MBXBF (MBXBF) Stock Price & Analysis
MBXBF (MBXBF) rose 0.92% to USD 0.22 as of July 25, 2026 at 15:02 UTC, according to Nexqual real-time market data.
MBXBF last closed at USD 0.22; the session ranged USD 0.23–0.23 on volume of 4,500 shares. Market capitalization is $30.11M, with a 52-week range of USD 0.15–0.23 (OQX). Source: Nexqual, July 25, 2026 at 15:02 UTC.
Key Statistics (as of July 25, 2026 at 15:02 UTC)
| Price | USD 0.22 |
|---|---|
| Change | ▲ 0.92% (up) |
| Previous Close | USD 0.22 |
| Open | USD 0.23 |
| Day Range | USD 0.23 – 0.23 |
| 52-Week Range | USD 0.15 – 0.23 |
| Volume | 4,500 shares |
| Market Cap | $30.11M |
| Exchange | OQX |
Technical Analysis (MBXBF)
Nexqual's technical model rates MBXBF "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 15:02 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.88 (neutral) |
| vs SMA50 | Above (USD 0.2) |
| MACD | 0 (positive) |
Analyst Ratings (MBXBF)
Wall Street analysts rate MBXBF "None", per Nexqual as of July 25, 2026 at 15:02 UTC.
| Consensus Rating | None |
|---|
Earnings (MBXBF)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $3.78M |
Source: Nexqual, July 25, 2026 at 15:02 UTC.
Financials & Fundamentals (MBXBF)
| Total Revenue | $14.81M |
|---|---|
| Revenue Growth (YoY) | -36.60% |
| Gross Margin | +42.49% |
| Operating Margin | -37.37% |
| Profit Margin | -38.62% |
| ROE | -20.36% |
| Debt / Equity | 27.03 |
| Current Ratio | 5.35 |
| Total Cash | $8.13M |
| Total Debt | $6.80M |
| Free Cash Flow | $-4.11M |
Source: Nexqual, July 25, 2026 at 15:02 UTC.
Financial Health Score (MBXBF)
Nexqual rates MBXBF's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:02 UTC.
| Growth | Critical — Revenue -24% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $8M cash vs $7M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -20%, ROA -8.6% |
Ownership (MBXBF)
| Insider Ownership | +14.81% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 137.50M |
| Float | 114.87M |
Source: Nexqual, July 25, 2026 at 15:02 UTC.
Leadership (MBXBF)
MBXBF is led by Cameron L. Groome, President, CEO & Director, per Nexqual as of July 25, 2026 at 15:02 UTC.
| President, CEO & Director | Cameron L. Groome |
|---|---|
| Chief Financial Officer | James S. Currie |
| Chief Operating Officer | Kenneth Hughes |
| Senior Vice President of Sales & Business Development | Phillip Casselli |
| Senior Vice President of Scientific Affairs | Mark Luscher |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRBCF | Sirona Biochem Corp. | USD 0.01 | ▲ 0% |
| AVCNF | Avicanna Inc. | USD 0.1 | ▼ 0.99% |
| BIOAF | BIOASIS TECHNOLOGIES INC | USD 0 | ▲ 0% |
| CVALF | Covalon Technologies Ltd. | USD 1.54 | ▲ 1.32% |
| EMMA | Emmaus Life Sciences, Inc. | USD 0.01 | ▼ 0.26% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:02 UTC. This page is informational and not investment advice.